Press Room

5th European Conference on Pharmaceutics

Start
Tuesday, March 25, 2025 - 16:20
End
Tuesday, March 25, 2025 - 17:00
Location: Porto, Portugal
Hovione session at the 5th European Conference on Pharmaceuticals | Hovione

Interested in innovative dosage forms and advanced therapeutic technologies? Porto is hosting renowned industry experts, academia and the next generation of researchers to share the latest advances and Cláudia Pina Costa, proudly representing Hovione’s young scientists, will join the conversation with an oral session on “Key parameters for nasal dry powders performance characterization”. 

Can’t make it to Porto to attend the 5th European Conference on Pharmaceutics? Connect with our Inhalation and Nasal experts at RDD Europe next May. 

Learn more about our Inhalation and Nasal offering.

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025